Exhibit 10.2

AMENDMENT NO. 1 & CONSENT

     THIS AMENDMENT NO. 1 & CONSENT dated as of September 22, 2003 (this
“Amendment”) of the Credit Agreement referenced below is by and among
BIORELIANCE CORPORATION, a Delaware corporation (“BioReliance”), BIORELIANCE
(GLASGOW) LIMITED, a Scottish private limited company (the “Foreign Borrower”;
together with BioReliance, the “Borrowers”), the Guarantors and Lenders party
hereto and BANK OF AMERICA, N.A., as Administrative Agent, Security Trustee and
L/C Issuer. Capitalized terms used but not otherwise defined herein shall have
the meanings provided in the Credit Agreement.

W I T N E S S E T H

     WHEREAS, a $60 million revolving credit and term loan facility has been
established in favor of the Borrowers pursuant to the terms of that Credit
Agreement dated as of August 12, 2003 (as amended and modified, the “Credit
Agreement”) among the Borrowers, the Guarantors and Lenders party thereto and
Bank of America, N.A., as Administrative Agent, Security Trustee and L/C Issuer;

     WHEREAS, the parties hereto have agreed to certain modifications to the
Credit Agreement on the terms and conditions set forth herein;

     NOW, THEREFORE, in consideration of these premises and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties agree as follows:

     SECTION 1 Amendments to the Credit Agreement. The Credit Agreement is
hereby amended in the following respects:

     1.1 Each of the cover page and the introductory paragraph is amended by
replacing the reference to “BIORELIANCE (GLASGOW) LTD.” with “BIORELIANCE
(GLASGOW) LIMITED” and the signature page to the Credit Agreement executed by
the Foreign Borrower is replaced with a corrected signature page for the Foreign
Borrower in the form attached as Schedule 1.1 hereto.

     1.2 Each of the following definitions in Section 1.01 (Defined Terms) is
amended and replaced in its entirety to read as follows:

       “BUKH” means BioReliance UK Holdings Limited, a Scottish private limited
company and Wholly Owned Subsidiary of BioReliance Acquisitions, Inc.

       “Q-One” means Q-One Biotech Group Limited, a Scottish private limited
company.

     1.3 Section 5.02 (Conditions Precedent to the Initial Credit Extensions) is
amended as follows:

       (a) Subsection (p) is amended by inserting a comma and deleting the word
“and” immediately prior to the reference to “8.03” and by adding “and 8.04
(Fundamental Changes)” at the end thereof;

       (b) Each of subsections (a) and (b) of Section 5.02 is amended and
replaced in its entirety to read as follows:

       (a) Joinder Agreements. Receipt by the Administrative Agent of duly
executed counterparts of the Joinder Agreements of (i) BUKH joining such Person
as a Domestic Guarantor and (ii) BUKS joining such Person as a Foreign
Guarantor.

 

--------------------------------------------------------------------------------

 

       (b) Other Credit Documents. Receipt by the Administrative Agent of duly
executed counterparts of each of the Notes, the Domestic Security Agreement, the
Domestic Pledge Agreement, each Foreign Security Agreement and each Foreign
Pledge Agreement required to be delivered as of the Initial Funding Date, and
each other document required to be delivered as of the Initial Funding Date in
connection with any of the foregoing (provided each such document or agreement
governed by Scottish law shall be an executed original rather than executed
original counterparts).

       (c) Each of subsections (i) and (ii) of Section 5.02(e) is amended and
replaced in its entirety to read as follows:

       (i) consolidated financial statements of the Consolidated Group for the
fiscal years ended December 31, 2000, 2001 and 2002, including balance sheets
and income and cash flow statements, prepared in conformity with GAAP and
audited by independent public accountants of recognized national standing (the
“BioReliance Financial Statements”);

       (ii) consolidated financial statements of Q-One and its Subsidiaries for
the fiscal years ended March 31, 2001, 2002 and 2003, including balance sheets
and income and cash flow statements, prepared in conformity with UK GAAP and
audited by independent public accountants of recognized standing reasonably
acceptable to the Administrative Agent (the “Q-One Financial Statements”);

       (d) Subsection (n) is amended and replaced in its entirety to read as
follows:

       (n) [Intentionally omitted.]

     1.4 Each of Section 6.05 (Financial Statements) and Section 7.01 (Financial
Statements) is amended by deleting each reference to the phrase “and
consolidating” therein.

     1.5 Section 6.19 (Business Locations) is amended by deleting the phrase
“located in the United States” therein.

     1.6 Subsection (b) of Section 7.13 (Pledged Capital Stock) is amended by
inserting the phrase “subject to Section 7.18(b)” at the beginning of clause
(iii) thereof.

     1.7 Section 7.18 (Post-Funding Deliveries) is amended and replaced in its
entirety to read as follows:

     7.18 Post-Funding Deliveries.

     Deliver each of the following to the Administrative Agent, in each case in
form and substance reasonably acceptable to the Administrative Agent:

       (a) Transaction Deliveries. Immediately following consummation of the
Transaction, deliver:

       (i) each item required to be delivered pursuant to Sections 7.12(b),
7.13(b) (other than items referenced in clause (iii) thereof, which are subject
to subsection (b) below) and 7.14(b);

2

--------------------------------------------------------------------------------

 

       (ii) with respect to Satron, Q-One and each of their Subsidiaries (other
than Quip Technology), duly executed notices of grant of security interest as
are necessary, in the Administrative Agent’s reasonable discretion, to perfect
the Administrative Agent’s security interest in the intellectual property of
such Credit Parties; and

       (iii) with respect to the Glasgow Mortgage and each Foreign Security
Agreement executed by any of Satron, Q-One or any of their Subsidiaries, a
Form 410 duly completed and executed in respect thereof;

       (iv) with respect to the Glasgow Mortgage, the Land Certificate relating
thereto, the Charge Certificate in favor of Bank of Scotland relative to Q-One’s
interest therein, a duly executed Discharge of the Standard Security comprised
in such Charge Certificate, a Form 419a in respect of such Discharge,
appropriate searches in the Land Register of Scotland evidencing Q-One’s
exclusive ownership thereof and showing no Liens (other than Permitted Liens)
affecting the same other than such Standard Security, Q-One’s Scottish counsel’s
letter of obligation in usual Scottish form in respect of the Land Register and
on behalf of Q-One in respect of the Register of Charges and all relevant
registration forms and dues to enable the registration of the Glasgow Mortgage
as a first charge over the same;

       (v) evidence (including certified copies of applicable documents and
resolutions) that each of Satron, Q-One and each of their Subsidiaries (other
than Quip Technology and Q-One Biotech, Inc.) has complied with Sections 151-158
of the UK Companies Act 1985 and receipt of an auditors’ non-statutory report
and a board memorandum in relation to the net asset position of each such
Person; and

       (vi) evidence that (A) the existing Indebtedness pursuant to that certain
overdraft facility provided by the Bank of Scotland to Q-One has been terminated
(provided that Q-One may continue to maintain current, deposit, checking and
other operating accounts with the Bank of Scotland) and (B) all Liens (other
than Permitted Liens) securing obligations in connection with such Indebtedness
have been released.

       (b) Pledge of Stock of Subsidiaries of the Foreign Borrower. Within
thirty days of the Initial Funding Date, deliver:

       (i) each of the items referenced in clause (iii) of Section 7.13(b), and
all certificates evidencing any certificated Capital Stock pledged to the
Administrative Agent or the Security Trustee pursuant to any Foreign Pledge
Agreement delivered pursuant thereto, together with duly executed in blank,
undated stock powers attached thereto (unless such stock powers are deemed
unnecessary by the Administrative Agent in its reasonable discretion under the
Law of the jurisdiction of incorporation of such Person), provided that it is
acknowledged that the Foreign Borrower may, after the Initial Funding Date,
request the Lenders to consent to the extension of the thirty-day period for the
delivery of items in this subsection (b) so as to permit the adjudication of UK
stamp duty on the transfers of shares in Q-One and Satron to be submitted after
the final determination of the purchase price for such shares pursuant to the
purchase price adjustment provision in the Purchase Agreement;

       (ii) with respect to each of Satron, Q-One and each of their Subsidiaries
(other than Quip Technology and Q-One Biotech, Inc.), a certified copy of the
register of shareholders for such Person (A) evidencing that the Security
Trustee has been registered as holder of the issued share capital of such Person
as required under Section 7.13 pursuant to the applicable Foreign Pledge
Agreement and (B) identifying the registered

3

--------------------------------------------------------------------------------

 

  holders of all of the issued share capital of such Person immediately prior to
such registry of the Security Trustee; and

       (iii) with respect to the foregoing pledges, evidence of payment of taxes
(or exemption therefrom or any provisional adjudication in respect thereof) in
respect of such pledged shares, filings and related deliveries reasonably
necessary in connection therewith to perfect the security interests therein, and
opinions of counsel (provided that, with respect to enforceability of any
documents executed by a Foreign Credit Party, such opinions shall be of counsel
to the Administrative Agent).

       (c) Mortgaged Property Deliveries.

       (i) Within ninety days of the Initial Funding Date, deliver a duly
executed leasehold Mortgage with respect to the leasehold interest of
BioReliance in 9900 Blackwell Road, Rockville, Maryland 20850, together with a
standard ALTA (or reasonably equivalent) mortgagee title insurance commitment
marked-up (the “Marked Commitment”), reasonably acceptable to the Administrative
Agent, insuring the priority of such Mortgage over all other liens on such
Property (other than Permitted Liens, including the Leasehold Deed of Trust and
Security Agreement in favor of Bank of America securing the obligations of the
borrowers under that certain Amended and Restated Replacement Loan Agreement
dated as of October 31, 1997 among BioReliance (successor in interest to
Microbiological Associates, Inc.), the other borrowers party thereto and Bank of
America (successor in interest to NationsBank, N.A., successor in interest to
Maryland National Bank) evidencing a term loan in the current outstanding
principal amount of approximately $2.2 million), together with copies of
recorded documentation relating to any exceptions,

       (ii) within thirty days of the date of receipt of the recorded Mortgage,
deliver a standard ALTA (or reasonably equivalent) mortgagee policy consistent
with the Marked Commitment, and

       (iii) not later than delivery of the mortgagee policy pursuant to clause
(ii) above, to the extent necessary in connection with the issuance thereof,
deliver a copy of a recent ALTA (or reasonably equivalent) survey of such
Mortgaged Property by registered engineers or land surveyors.

       (d) Evidence of Insurance. Within ninety days of the Initial Funding
Date, deliver copies of insurance policies or certificates of insurance of the
Foreign Credit Parties and their Subsidiaries evidencing liability, flood hazard
and casualty insurance meeting the requirements set forth in the Credit
Documents, including naming the Security Trustee as additional interest on
behalf of the Lenders.

     1.8 Each of subsections (d) and (j) of Section 8.02 (Investments) is
amended and replaced in its entirety to read as follows:

       (d) Investments by any Domestic Credit Party in any Foreign Credit Party
in an aggregate amount for all such Investments in Foreign Credit Parties not to
exceed at any time outstanding the sum of $5,000,000 less the aggregate amount
of Dispositions permitted pursuant to Section 8.05(g);

       (j) Investments made in or to the Foreign Borrower (directly or
indirectly) for the purpose of enabling the Foreign Borrower to make payments of
principal and interest owing on

4

--------------------------------------------------------------------------------

 

  Foreign Term Loan to the extent, but only to the extent, that such amounts are
not otherwise available to the Foreign Borrower and a payment default would
otherwise result; and

     1.9 Subsection (g) of Section 8.05 (Dispositions) is amended and replaced
in its entirety to read as follows:

       (g) Dispositions of property by the Domestic Credit Parties to any
Foreign Credit Party in an aggregate amount for all such Dispositions to Foreign
Credit Parties not to exceed the sum of $5,000,000 less the aggregate amount of
Investments permitted pursuant to Section 8.02(d) outstanding at such time; and

     1.10 Subsection (a) of Section 11.01 (Amendments, Etc.) is amended and
replaced in its entirety to read as follows:

       (a) unless also consented to in writing by each Lender directly affected
thereby:

       (i) extend or increase the Commitment of any Lender (or reinstate any
Commitment terminated pursuant to Section 9.02) (it being understood and agreed
that a waiver of any condition precedent set forth in Section 5.03 or of any
Default or Event of Default is not considered an extension or increase in
Commitments of any Lender);

       (ii) postpone any date fixed by this Credit Agreement or any other Credit
Document for any payment of principal (excluding mandatory prepayments),
interest, fees or other amounts due to the Lenders (or any of them) hereunder or
under any other Credit Document, or waive any condition precedent set forth in
Section 5.03 during the continuance of any Event of Default under Section
9.01(a);

       (iii) reduce the principal of, or the rate of interest specified herein
on, any Loan or L/C Borrowing, or any fees or other amounts payable hereunder or
under any other Credit Document; provided, however, that only the consent of the
Required Lenders shall be necessary to amend the definition of “Default Rate” or
to waive any obligation of the Borrowers to pay interest at the Default Rate;

       (iv) change Section 2.12 or Section 9.03 in a manner that would alter the
pro rata sharing of payments required thereby;

       (v) change any provision of this Section 11.01(a) or the definition of
“Required Lenders” or any other provision hereof specifying the number or
percentage of Lenders required to amend, waive or otherwise modify any rights
hereunder or make any determination or grant any consent hereunder;

       (vi) waive the pledge of any Collateral under Section 7.13(a) and (b) or
Section 7.14(a) and (b) or, except in connection with a Disposition permitted
under Section 8.05, release all or substantially all of the Collateral; or

       (vii) waive the joinder of any Subsidiary under Section 7.12(a) and (b),
or release either Borrower or, except in connection with a merger or
consolidation permitted under Section 8.04 or a Disposition permitted under
Section 8.05, all or substantially all of the Guarantors, from its or their
obligations under the Credit Documents;

     SECTION 2 Consent. Notwithstanding the provisions of Section 8.13(c) of the
Credit Agreement, the Lenders hereby consent to allow the Credit Parties to
change the legal name of (a) Q-One Biotech Limited, a Scottish private limited
company, to “BioReliance Biotech Limited” and (b) Q-One

5

--------------------------------------------------------------------------------

 

Biotech, Inc., a Delaware corporation, to “BioReliance Biotech, Inc.”; in each
case not earlier than one Business Day following (i) the consummation of the
Transaction, (ii) the joinder of such Person as a Guarantor under the Credit
Agreement and (iii) the execution and delivery of the security documents to be
entered in connection with such joinder.

     SECTION 3 Conditions Precedent.

     3.1 This Amendment shall be effective immediately upon receipt by the
Administrative Agent, in form and substance satisfactory to the Administrative
Agent, of each of the following:

  (a)   counterparts of this Amendment duly executed by each Credit Party; and  
  (b)   counterparts of this Amendment duly executed by each Lender.

     SECTION 4 Miscellaneous.

     4.1 Immediately upon the effectiveness of this Amendment, the term “Credit
Agreement” (as used in any of the Credit Documents) shall mean the Credit
Agreement as amended and modified hereby. Except as amended and modified hereby,
all of the terms and provisions of the Credit Agreement and the other Credit
Documents (including schedules and exhibits thereto) shall remain in full force
and effect.

     4.2 The Credit Parties hereby affirm that, after giving effect to this
Amendment, (a) the representations and warranties set forth in the Credit
Agreement and the other Credit Documents are true and complete in all material
respects as of the date hereof (except those which expressly relate to an
earlier period) and (b) no Default or Event of Default exists or is continuing.

     4.3 Each Credit Party hereby represents and warrants that (a) the
execution, delivery and performance by such Credit Party of this Amendment has
been duly authorized by all necessary corporate or other organizational action;
(b) such Credit Party has duly executed and delivered this Amendment; (c) this
Amendment constitutes a legal, valid and binding obligation of such Credit
Party, enforceable against each such Credit Party in accordance with its terms
except as may be limited by applicable Debtor Relief Laws or general principles
of equity; (d) this Amendment does not (i) contravene the terms of such Credit
Party’s Organization Documents, (ii) conflict with or result in any material
breach or contravention of, or the creation of any Lien under (A) any material
Contractual Obligation to which such Credit Party is a party or (B) any order,
injunction, writ or decree of any Governmental Authority or any arbitral award
to which such Credit Party or its property is subject or (iii) violate any Law;
and (e) other than those that have already been obtained and are in full force
and effect, no approval, consent, exemption, authorization, or other action by,
or notice to, or filing with, any Governmental Authority or any other Person
with respect to any material Contractual Obligation is necessary or required in
connection with (i) the execution, delivery or performance by, or enforcement
against, any Credit Party of this Amendment or (ii) admissibility in evidence of
this Amendment under Scottish law.

     4.4 Each Guarantor (a) acknowledges and consents to all of the terms and
conditions of this Amendment, (b) affirms such Guarantor’s obligations under the
Credit Documents and (c) agrees that this Amendment does not operate to reduce
or discharge such Guarantor’s obligations under the Credit Documents.

     4.5 BioReliance agrees to pay all reasonable costs and expenses of the
Administrative Agent in connection with the preparation, execution and delivery
of this Amendment, including the reasonable fees and expenses of Moore & Van
Allen, PLLC.

     4.6 This Amendment may be executed in any number of counterparts, each of
which when so executed and delivered shall be deemed an original, and it shall
not be necessary in making proof of this

6

--------------------------------------------------------------------------------

 

Amendment to produce or account for more than one such counterpart. Delivery by
any party hereto of an executed counterpart of this Amendment by facsimile shall
be effective as such party’s original executed counterpart and shall constitute
a representation that such party’s original executed counterpart will be
delivered promptly.

     4.7 THIS AMENDMENT SHALL BE DEEMED TO BE A CONTRACT MADE UNDER, AND FOR ALL
PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK.

[remainder of page intentionally left blank]

7

--------------------------------------------------------------------------------

 

     IN WITNESS WHEREOF, each of the parties hereto has caused a counterpart of
this Amendment to be duly executed and delivered as of the date first above
written.

              BORROWERS:   BIORELIANCE CORPORATION, a Delaware corporation, as a
Borrower and, with respect to the Foreign Obligations, as a Guarantor          
            By:                

--------------------------------------------------------------------------------

        Name:             Title:                   Before this witness:  
BIORELIANCE (GLASGOW) LIMITED, a Scottish private limited company, as a Borrower
              By:       By:        

--------------------------------------------------------------------------------

     

--------------------------------------------------------------------------------

Name:       Name:     Title:       Title:     Address:                          
DOMESTIC GUARANTORS:   BIORELIANCE VIRAL MANUFACTURING, INC., a Delaware
corporation                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                           BIORELIANCE
MANUFACTURING, LLC, a Delaware
limited liability company                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                           BIORELIANCE TESTING
AND DEVELOPMENT, LLC, a
Delaware limited liability company                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                           BIORELIANCE
ACQUISITIONS, INC. , a Delaware corporation                       By:          
     

--------------------------------------------------------------------------------

        Name:             Title:    

 

--------------------------------------------------------------------------------

 

              FOREIGN GUARANTORS:   BIORELIANCE HOLDING GMBH, a German limited
liability
company                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                           BIORELIANCE
MANUFACTURING GMBH, a German limited
liability company                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                           BIORELIANCE GMBH, a
German limited liability
company                       By:                

--------------------------------------------------------------------------------

        Name:             Title:    

 

--------------------------------------------------------------------------------

 

          ADMINISTRATIVE AGENT:   BANK OF AMERICA, N.A., as Administrative Agent
and as Security Trustee               By:            

--------------------------------------------------------------------------------

    Name:         Title:               LENDERS:   BANK OF AMERICA, N.A., as a
Lender and as L/C Issuer               By:            

--------------------------------------------------------------------------------

    Name:         Title:    

 

--------------------------------------------------------------------------------

 

Schedule 1.1

     IN WITNESS WHEREOF, the parties hereto have caused this Credit Agreement to
be duly executed as of the date first above written.

                      BORROWERS: BIORELIANCE CORPORATION, a Delaware
corporation, as a Borrower and, with respect to the Foreign Obligations, as a
Guarantor                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                   Before this witness:  
BIORELIANCE (GLASGOW) LIMITED, a Scottish private limited company, as a Borrower
              By:       By:        

--------------------------------------------------------------------------------

     

--------------------------------------------------------------------------------

Name:       Name:     Title:       Title:     Address:                          
DOMESTIC GUARANTORS:   BIORELIANCE VIRAL MANUFACTURING, INC., a Delaware
corporation                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                           BIORELIANCE
MANUFACTURING, LLC, a Delaware
limited liability company                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                           BIORELIANCE TESTING
AND DEVELOPMENT, LLC, a
Delaware limited liability company                       By:                

--------------------------------------------------------------------------------

        Name:             Title:                           BIORELIANCE
ACQUISITIONS, INC. , a Delaware corporation                       By:          
     

--------------------------------------------------------------------------------

        Name:             Title: